Chasing Novartis, Amgen ushers Lp(a) drug into phase 3

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T06:40:13.662Z • Permanent link

Novartis and Amgen are now locked in a high-stakes game of catch-up, with the latter's novel Lp(a) inhibitor advancing into phase 3 clinical trials, following a similar path that has captivated the attention of many investors. This move comes hot on the heels of Novartis's own Lp(a) program, which has been touted as a potentially blockbuster opportunity, but has thus far been met with skepticism by some analysts. Amidst the fervor surrounding these two titans of the biotech world, it's essential to separate fact from fiction and drill down into the specifics of what's really happening.

Novartis has been quietly investing in its Lp(a) research since 2019, with the company initially partnering with the University of California, San Francisco (UCSF) to develop a treatment for the condition. The project has since expanded to include collaborations with several other leading institutions, including the University of Michigan and the University of Texas. Meanwhile, Amgen has been working in relative secrecy, with the company's Lp(a) program now boasting a substantial research team and a robust pipeline of compounds. The stakes are high, with both companies facing intense competition for market share in the rapidly expanding Lp(a) treatment space.

One key data point that may have contributed to Amgen's decision to push forward with its Lp(a) program is the growing body of evidence linking elevated Lp(a) levels to cardiovascular disease. Studies have consistently shown that individuals with high Lp(a) levels are at increased risk of heart attack and stroke, making Lp(a) a compelling target for treatment. This trend is expected to continue, with the global Lp(a) treatment market projected to reach $1.4 billion by 2025, up from a mere $400 million in 2020.

The implications of this Lp(a) treatment landscape are far-reaching, with several major players set to be impacted by the outcome of these clinical trials. Novartis, in particular, is under pressure to deliver on its Lp(a) promises, with investors eagerly awaiting updates on the program's progress. Meanwhile, Amgen is poised to capitalize on the growing demand for Lp(a) treatments, with the company's existing pipeline of cardiovascular therapies providing a significant competitive advantage. Research communities, too, are likely to be influenced by the success or failure of these trials, with the development of new Lp(a) treatments potentially unlocking fresh avenues for innovation in the field.

The Lp(a) treatment space is also likely to have significant implications for the broader biotech industry, with several major players set to be impacted by the outcome of these trials. Companies such as Pfizer and Sanofi are already exploring the therapeutic potential of Lp(a) inhibitors, while others, such as GlaxoSmithKline, are focusing on the development of more traditional cardiovascular treatments. As the market continues to evolve, it's essential for professionals in the field to stay informed about the latest developments and trends.

The Lp(a) treatment landscape is not without its challenges, however, with several competing approaches vying for attention. For example, Novartis's Lp(a) program has been criticized for its lack of transparency, with some analysts questioning the company's decision to pursue a novel Lp(a) inhibitor rather than focusing on more established cardiovascular treatments. Meanwhile, rival companies such as AstraZeneca and Eli Lilly are exploring alternative approaches, including the development of Lp(a)-lowering therapies that target other key cardiovascular risk factors.